{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T23:23:12Z","timestamp":1773876192334,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:00:00Z","timestamp":1763856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"publisher","award":["10758"],"award-info":[{"award-number":["10758"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.breast.2025.104666","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:05:14Z","timestamp":1764029114000},"page":"104666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Outcomes for ER-positive CHEK2 c.1100delC breast cancer patients compared with breast cancer patients without the variant"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1826-5344","authenticated-orcid":false,"given":"Maartje A.C.","family":"Schreurs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muriel A.","family":"Adank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernadette A.M.","family":"Heemskerk-Gerritsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoinette","family":"Hollestelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nyr\u00e9e","family":"Smallenbroek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christi J.","family":"van Asperen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margreet G.E.M.","family":"Ausems","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irma","family":"van de Beek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geertruida H.","family":"de Bock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Boere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liselotte P.","family":"van Hest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim J.A.F.","family":"van Kaam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"de Munck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet R.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Jager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjanka K.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6763-0857","authenticated-orcid":false,"given":"Maartje J.","family":"Hooning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.breast.2025.104666_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ng879","article-title":"Low-penetrance susceptibility to breast cancer due to CHEK2(\u2217)1100delC in noncarriers of BRCA1 or BRCA2 mutations","volume":"31","author":"Meijers-Heijboer","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.breast.2025.104666_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1023\/B:BREA.0000010697.49896.03","article-title":"Excess risk for contralateral breast cancer in CHEK2\u22171100delC germline mutation carriers","volume":"83","author":"Broeks","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2025.104666_bib3","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/bjc.2014.306","article-title":"Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy","volume":"111","author":"Kriege","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2025.104666_bib4","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/sj.bjc.6604228","article-title":"Risk for contralateral breast cancer among carriers of the CHEK2\u22171100delC mutation in the WECARE study","volume":"98","author":"Mellemkj\u00e6r","year":"2008","journal-title":"Br J Cancer"},{"issue":"15","key":"10.1016\/j.breast.2025.104666_bib5","doi-asserted-by":"crossref","first-page":"16142","DOI":"10.1002\/cam4.6272","article-title":"Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival","volume":"12","author":"Morra","year":"2023","journal-title":"Cancer Med"},{"issue":"35","key":"10.1016\/j.breast.2025.104666_bib6","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1200\/JCO.2012.42.7336","article-title":"CHEK2\u22171100delC heterozygosity in women with breast cancer associated with early death, breast cancer\u2013specific death, and increased risk of a second breast cancer","volume":"30","author":"Weischer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.104666_bib7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/jmg.2004.019737","article-title":"Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2\u22171100delC variant","volume":"41","author":"de Bock","year":"2004","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.breast.2025.104666_bib8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1200\/JCO.2006.06.3024","article-title":"Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2\u22171100delC germline mutation","volume":"25","author":"Schmidt","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2025.104666_bib9","article-title":"Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes","volume":"8","author":"Breast Cancer Association","year":"2022","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.breast.2025.104666_bib10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13058-023-01653-0","article-title":"Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile","volume":"25","author":"Smid","year":"2023","journal-title":"Breast Cancer Res"},{"issue":"3","key":"10.1016\/j.breast.2025.104666_bib11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ajhg.2023.02.003","article-title":"The impact of coding germline variants on contralateral breast cancer risk and survival","volume":"110","author":"Morra","year":"2023","journal-title":"Am J Hum Genet"},{"issue":"Suppl. 2","key":"10.1016\/j.breast.2025.104666_bib12","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1525-1438.2006.00694.x","article-title":"Association between the CHEK2\u22171100delC germ line mutation and estrogen receptor status","volume":"16","author":"de Bock","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.breast.2025.104666_bib13","first-page":"159","article-title":"Stand van zaken - CHEK2-mutatie in Nederlandse borstkankerfamilies: uitbreiding van de genetische diagnostiek op borstkanker","author":"Adank","year":"2015","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.breast.2025.104666_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.100870","article-title":"Management of individuals with germline pathogenic\/likely pathogenic variants in CHEK2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","author":"Hanson","year":"2023","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.breast.2025.104666_bib15","first-page":"1045","article-title":"The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies","volume":"10","author":"Kreutzfeldt","year":"2020","journal-title":"Am J Cancer Res"},{"issue":"3","key":"10.1016\/j.breast.2025.104666_bib16","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.2009.23.1274","article-title":"Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen","volume":"28","author":"Dowsett","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10001","key":"10.1016\/j.breast.2025.104666_bib17","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.breast.2025.104666_bib18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.breast.2025.104666_bib19","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.breast.2025.104666_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-086688","article-title":"Cohort profile: a nationwide study in Dutch CHEK2 c.1100delC families using the infrastructure of the HEreditary Breast and Ovarian cancer study Netherlands - Hebon-CHEK2","volume":"14","author":"Schreurs","year":"2024","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.breast.2025.104666_bib21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41416-020-01161-4","article-title":"The lingering mysteries of metastatic recurrence in breast cancer","volume":"124","author":"Riggio","year":"2021","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.breast.2025.104666_bib22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods"},{"issue":"19","key":"10.1016\/j.breast.2025.104666_bib23","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.breast.2025.104666_bib24","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/sj.bjc.6605062","article-title":"Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates?","volume":"100","author":"Azzato","year":"2009","journal-title":"Br J Cancer"},{"issue":"13","key":"10.1016\/j.breast.2025.104666_bib25","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO-24-02442","article-title":"Breast, colorectal, and pancreatic cancer mortality with pathogenic variants in ATM, CHEK2, or PALB2","volume":"43","author":"Veenstra","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2025.104666_bib26","article-title":"Rethinking contralateral breast cancer: latest insights on risk, prevention, and outcomes","volume":"4","author":"Hosseini","year":"2025","journal-title":"Clinical Cancer Bulletin"},{"issue":"2","key":"10.1016\/j.breast.2025.104666_bib27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ijc.31051","article-title":"Contralateral breast cancers: independent cancers or metastases?","volume":"142","author":"Begg","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.breast.2025.104666_bib28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.21037\/tbcr-24-53","article-title":"CHEK2 variants, breast cancer, and implications for management: a narrative review","volume":"6","author":"Conde","year":"2025","journal-title":"Transl Breast Cancer Res"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625008859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625008859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:48:07Z","timestamp":1773848887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977625008859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":28,"alternative-id":["S0960977625008859"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2025.104666","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes for ER-positive CHEK2 c.1100delC breast cancer patients compared with breast cancer patients without the variant","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2025.104666","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104666"}}